What question did this study set out to answer?

The study aims to evaluate the effectiveness of KFLC-Index as a diagnostic tool for differentiating between MOGAD, AQP4-NMOSD, and MS.

April 3, 2026Neurology1 citationsOpen Access

View Full Paper

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS

ATApolline TournierObservatoire Français de la Sclérose en Plaques AGAntoine GavoilleUniversité Claude Bernard Lyon 1 JPJulie PiqueUniversité Claude Bernard Lyon 1

Key Points

The study aims to evaluate the effectiveness of KFLC-Index as a diagnostic tool for differentiating between MOGAD, AQP4-NMOSD, and MS.
Performed a comparative analysis of KFLC-Index and oligoclonal bands in cerebrospinal fluid.
Included patients diagnosed with MOGAD, AQP4-NMOSD, and MS.
Assessed diagnostic performance metrics of both biomarkers.
KFLC-Index showed superior diagnostic accuracy in distinguishing MS from MOGAD and AQP4-NMOSD.
The performance of KFLC-Index was higher than that of oligoclonal bands.

Abstract

The differential diagnosis between aquaporin-4-immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), and multiple sclerosis (MS) can be complex. Kappa free light chain index (KFLC-Index) emerged as an effective biomarker for distinguishing patients with MS from patients with other conditions. The main aim of this study was to assess the diagnostic performance of KFLC-Index in differentiating MOGAD, AQP4-NMOSD, and MS and to compare it with CSF-restricted oligoclonal bands (OCB) performance.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS

Key Points

Abstract

Cite This Study

Also Consider

Also Consider